The FAK inhibitor, VS6063, has completed the phase II clinical trials and showed monotherapy demonstrated modest clinical activity and was generally well-tolerated [30], providing a more feasible treatment for NSCLC metastasis. Here, PTK2 is linked to non-small cell lung carcinoma.